Somnus Therapeutics Licenses Sleep Candidate From SkyePharma
This article was originally published in The Pink Sheet Daily
Somnus will pay SkyePharma up to $35 million in milestones for development of the non-benzodiazepine sleep therapy.
You may also be interested in...
Extended-release ropinirole uses Skye’s proprietary GeoMatrix technology to provide steady levels over 24 hours.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.